Lisa Wong, MD
Endocrinology, Diabetes & Metabolism · Honolulu, HINPI 1891760260
Payments from drug & device makers
Across 529 payments — averaging $22.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Amgen$2K
- Novo Nordisk$2K
- Lilly USA, LLC$1K
- Boehringer Ingelheim$1K
- Sanofi-aventis U.S. LLC$716
- AstraZeneca$646
- plus $4K from 25 others
What the payments were for
- Food & beverage$11,80799%
- Education$1411%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Amgen(2 entities) | 81 | $2,320 |
| Novo Nordisk | 101 | $1,873 |
| Lilly USA, LLC | 72 | $1,294 |
| Boehringer Ingelheim | 48 | $1,196 |
| Sanofi-aventis U.S. LLC | 38 | $716 |
| AstraZeneca | 22 | $646 |
| Dexcom, Inc. | 28 | $571 |
| Corcept Therapeutics | 16 | $520 |
| Amarin Pharma, Inc. | 22 | $419 |
| Pfizer | 7 | $314 |
| Insulet Corporation | 13 | $302 |
| Mannkind Corporation | 13 | $288 |
| Medtronic(2 entities) | 10 | $237 |
| Bayer | 10 | $220 |
| Tandem Diabetes Care, Inc. | 11 | $216 |
| Abbott | 5 | $102 |
| Biohaven Pharmaceuticals, Inc. | 4 | $90 |
| Kyowa Kirin, Inc. | 3 | $81 |
| Radius Health, Inc. | 3 | $76 |
| Biohaven Pharmaceutical Holding Company Ltd. | 3 | $64 |
| Esperion Therapeutics, Inc. | 3 | $62 |
| Johnson & Johnson | 3 | $52 |
| Neurocrine Biosciences, Inc. | 1 | $51 |
| Vistapharm, Inc. | 2 | $40 |
| BETA Bionics, Inc. | 2 | $40 |
| Regeneron Healthcare Solutions, Inc. | 2 | $36 |
| Merck | 2 | $31 |
| AbbVie | 1 | $29 |
| Xeris Pharmaceuticals, Inc. | 1 | $24 |
| Novartis | 1 | $23 |
| RGH Enterprises LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$11,949 in reported general payments places this provider in the 75th percentile of 22 endocrinology, diabetes & metabolism providers in Hawaii.
See all endocrinology, diabetes & metabolism providers in Hawaii →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 127 | $178,539 |
| OzempicSemaglutide | 98 | $172,065 |
| MounjaroTirzepatide | 91 | $169,666 |
| ProliaDenosumab | 28 | $48,578 |
| Tresiba Flextouch U-200Insulin Degludec | 23 | $44,517 |
| Tresiba Flextouch U-100Insulin Degludec | 51 | $43,536 |
| TrulicityDulaglutide | 18 | $41,181 |
| KerendiaFinerenone | 24 | $39,524 |
| VascepaIcosapent Ethyl | 31 | $27,746 |
| JanuviaSitagliptin Phosphate | 21 | $27,273 |
| FarxigaDapagliflozin Propanediol | 21 | $22,823 |
| Novolog FlexpenInsulin Aspart | 71 | $20,510 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 21 | $20,250 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 57 | $12,109 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 85 | $10,861 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $1,294 | $210,847109 claims |
| Boehringer IngelheimJardiance | $1,196 | $178,539127 claims |
| Novo NordiskOzempic | $1,873 | $172,06598 claims |
| AmgenProlia | $2,320 | $48,57828 claims |
| BayerKerendia | $220 | $39,52424 claims |
| MerckJanuvia | $31 | $27,27321 claims |
| AstraZenecaFarxiga | $646 | $22,82321 claims |
| AbbVieSynthroid | $29 | $2,68748 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 22 endocrinology, diabetes & metabolism providers in Hawaii.
Other endocrinology, diabetes & metabolism in Honolulu
- Cindy PauHonolulu$8.2M
- Alan ParsaHonolulu$4.1M
- Kelsey Shikuma LeeHonolulu$19K
- Anna Melissa LoHonolulu$13K
- Eric LeeHonolulu$3K
- Isabel CasimiroHonolulu$2K
- Se Mo SuhHonolulu$2K
- Chanhaeng RheeHonolulu$2K
- Kamonkiat WirunsawanyaHonolulu$1K
- Jennifer LohHonolulu$890
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.